生命科学资讯

Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout

TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio

Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline

Thermo Fisher Scientific: Recovery In Life Sciences Solutions (NYSE:TMO) - Seeking Alpha

Assessing Agilent Technologies (A) Valuation After Recent Share Price Softness and Long Term Gains - Yahoo Finance

Ascendis wins FDA approval of dwarfism drug

Illumina Inc (ILMN) Trading Down 2.84% on Mar 2 - GuruFocus

UniQure says FDA wants another study of Huntington’s gene therapy

Roche pill succeeds in another MS study, but approval questions linger

United Therapeutics to take pulmonary hypertension drug to FDA for approval

Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC

BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline

United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition

UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy

FDA fully releases clinical hold on Intellia CRISPR gene therapy trials

Thermo Fisher Scientific Launches New Color-Based (Chromogenic) Culture Media to Help Detect Candida Infections Faster*, Including Drug-Resistant Candida auris - BioSpace

Roche gets third pivotal win with MS drug, but liver signal could be a problem

FDA lifts hold on second Intellia Phase 3 gene editing trial

Stifel raises 10X Genomics stock price target on product adoption - Investing.com

Uniqure falls as FDA demands new trial for Huntington’s gene therapy